Actively Recruiting
Led by Yi Zhang · Updated on 2026-03-12
266
Participants Needed
4
Research Sites
13 weeks
Total Duration
Y
Yi Zhang
Lead Sponsor
T
The First People's Hospital of Yunnan
Collaborating Sponsor
Researchers are evaluating the use of moxibustion to prevent hemorrhagic cystitis (HC) in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) for blood diseases. This multicenter, randomized controlled study plans to enroll 266 patients aged 14 to 60 years with pernicious blood diseases or severe aplastic anemia receiving allo-HSCT. The goal is to assess whether moxibustion can reduce the incidence and severity of HC after transplantation. Participants are randomly divided into two groups. The experimental group receives moxibustion treatment applied to specific points (Zhongji, Guanyuan, and Qihai) for 30 minutes daily starting the first day after HSCT until day 14 post-transplant. The control group receives conventional symptomatic treatment. Urine tests for routine analysis and viruses are collected at admission, day 1, day 14, symptom onset, and remission of HC. Routine urine tests continue every 7 days for 100 days. During the study, researchers monitor HC symptoms daily in affected patients, including pain and severity scores, medication use, and traditional Chinese medicine evidence. Outcomes include highest pain score within 100 days post-transplant, incidence of HC, blood cell implantation rates, graft-versus-host disease, viral reactivation, infections, and mortality. Participants are followed for 100 days to evaluate these outcomes and treatment effects.
CONDITIONS
Moxibustion for the Prevention of Hemorrhagic Cystitis After Allo-HSCT
You may qualify if you...
You will not qualify if you...
Complete this quick 3-step screening to check your eligibility
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 15 days
Participants receive moxibustion once daily for 30 minutes starting on the first day after allogeneic hematopoietic stem cell transplantation (HSCT) until the 14th day after transplantation, or receive conventional symptomatic treatment.
Daily visits for up to 15 days
Duration - Up to 100 days
Participants are monitored for outcomes including pain scores, incidence of hemorrhagic cystitis, graft implantation rates, graft-versus-host disease, viral reactivation, infection, and mortality for up to 100 days after transplantation.
Regular follow-up visits during the 100 days post-transplant
Total: 4 locations
1
Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou
Zhengzhou, Henan, China, 450002
Actively Recruiting
2
Yi Zhang
Wuhan, Hubei, China, 430000
Actively Recruiting
3
Hematology Department, The First People's Hospital of Yunnan
Kunming, Yunnan, China, 650032
Actively Recruiting
4
Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou
Hangzhou, Zhejiang, China, 311121
Not Yet Recruiting
Y
Yi Zhang, Dr
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Alicia K Chang, Marc D Foca, Zhezhen Jin...
https://pubmed.ncbi.nlm.nih.gov/27378008C Mackall, T Fry, R Gress...
https://pubmed.ncbi.nlm.nih.gov/19861978Cesar Homero Gutiérrez-Aguirre, Alejandra Celina Esparza-Sandoval, Alain Palomares-Leal...
https://pubmed.ncbi.nlm.nih.gov/33814347Tina Dalianis, Per Ljungman
https://pubmed.ncbi.nlm.nih.gov/21498717R Manikandan, Santosh Kumar, Lalgudi N Dorairajan
https://pubmed.ncbi.nlm.nih.gov/20877590N H Khojasteh, M Zakerinia, M Ramzi...
https://pubmed.ncbi.nlm.nih.gov/10812128Marcos Arango, Doris Cardona
https://pubmed.ncbi.nlm.nih.gov/32417488Chiara Visintini, Margherita Venturini, Alvisa Palese
https://pubmed.ncbi.nlm.nih.gov/31446264